These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 18245109

  • 21. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F.
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [Abstract] [Full Text] [Related]

  • 23. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR, Engstrand S, Berglin E, Johnson O.
    Scand J Rheumatol; 2006 Dec; 35(2):107-11. PubMed ID: 16641043
    [Abstract] [Full Text] [Related]

  • 24. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 25. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group.
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [Abstract] [Full Text] [Related]

  • 26. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 27. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [Abstract] [Full Text] [Related]

  • 28. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis.
    Mulleman D, Chu Miow Lin D, Ducourau E, Emond P, Ternant D, Magdelaine-Beuzelin C, Valat JP, Paintaud G, Goupille P.
    Ther Drug Monit; 2010 Apr; 32(2):232-6. PubMed ID: 20216124
    [Abstract] [Full Text] [Related]

  • 29. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH, Bingham SJ, Bryer D, Emery P.
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [Abstract] [Full Text] [Related]

  • 30. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
    Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M, Scott DG.
    Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
    [Abstract] [Full Text] [Related]

  • 31. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

  • 32. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [Abstract] [Full Text] [Related]

  • 33. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
    Gerli R, Lunardi C, Bocci EB, Bobbio-Pallavicini F, Schillaci G, Caporali R, Bistoni O, Pirro M, Pitzalis C, Montecucco C.
    J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
    [Abstract] [Full Text] [Related]

  • 34. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

  • 35. [Clinical experience with infliximab administration in patients with rheumatoid arthritis (according to Russian register data)].
    Lukina GV, Sigidin IaA, Nasonov EL.
    Ter Arkh; 2009 Jun; 81(8):65-9. PubMed ID: 19799204
    [Abstract] [Full Text] [Related]

  • 36. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study.
    van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA.
    Ann Rheum Dis; 2012 Nov; 71(11):1849-54. PubMed ID: 22504561
    [Abstract] [Full Text] [Related]

  • 37. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [Abstract] [Full Text] [Related]

  • 38. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.
    Thurlings RM, Vos K, Gerlag DM, Tak PP.
    Arthritis Rheum; 2008 Dec; 58(12):3657-64. PubMed ID: 19035505
    [Abstract] [Full Text] [Related]

  • 39. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.
    Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN.
    Fundam Clin Pharmacol; 2009 Oct; 23(5):595-600. PubMed ID: 19563510
    [Abstract] [Full Text] [Related]

  • 40. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.